Minimal sequence variability of the region of HIV-1 integrase targeted by the Abbott RealTime HIV-1 viral load assay in clinical specimens with reduced susceptibility to raltegravir

J Virol Methods. 2013 Nov;193(2):693-6. doi: 10.1016/j.jviromet.2013.07.028. Epub 2013 Jul 25.

Abstract

The Abbott RealTime (ART) HIV-1 assay targets the integrase region and is designed to tolerate mismatches. Variability in integrase sequences comprising the assay target regions from >1000 clinical specimens submitted for phenotypic and genotypic raltegravir resistance testing were analyzed. In this large collection of sequences from clinical specimens, the number and location of raltegravir resistance associated mutations did not differ from those tested previously and shown not to result in under-estimation of viral loads.

Keywords: Assay; HIV; Integrase inhibitor resistance; Sequence variability.

MeSH terms

  • Anti-HIV Agents / pharmacology*
  • Drug Resistance, Viral*
  • Genetic Variation
  • HIV Infections / virology*
  • HIV Integrase / genetics*
  • HIV-1 / drug effects
  • HIV-1 / genetics*
  • HIV-1 / isolation & purification
  • Mutation
  • Pyrrolidinones / pharmacology*
  • Raltegravir Potassium
  • Viral Load / methods*

Substances

  • Anti-HIV Agents
  • Pyrrolidinones
  • Raltegravir Potassium
  • HIV Integrase
  • p31 integrase protein, Human immunodeficiency virus 1